for the NHLBI LAM Registry Group BACKGROUND: The natural history of lymphangioleiomyomatosis (LAM) is mainly derived from retrospective cohort analyses, and it remains incompletely understood. A National Institutes of Health LAM Registry was established to define the natural history and identify prognostic biomarkers that can help guide management and decision-making in patients with LAM.
Lymphangioleiomyomatosis (LAM) is a progressive, female-predominant, low-grade neoplasm driven by mutations in the tuberous sclerosis complex (TSC) genes. [1] [2] [3] These mutations lead to constitutive activation of the mechanistic target of rapamycin (mTOR) pathway, which promotes chaotic lymphatic channel development through expression of lymphangiogenic growth factors such as vascular endothelial growth factor-C and vascular endothelial growth factor-D (VEGF-D). 4, 5 It also drives the metastasis of neoplastic smooth muscle-like cells (LAM cells) leading to progressive cystic remodeling of the pulmonary parenchyma. 1, 3 The Multicenter International LAM Efficacy of Sirolimus (MILES) trial showed that treatment with sirolimus, an mTOR inhibitor, could stabilize lung function decline and improve quality of life in patients with LAM. 6 Based on these results, sirolimus was approved by the US Food and Drug Administration for the treatment of patients with LAM in the United States in 2015. 7 Optimal selection of patients for treatment requires a clear understanding of the natural history of LAM, as well as the factors that influence disease progression and treatment response.
Almost 20 years ago, the National Heart, Lung, and Blood Institute (NHLBI) established a national LAM registry. 8 For a period of 3 years (1998-2001), a total of 246 women with LAM were enrolled at six different US sites and followed up for a period of up to 5 years, through 2003. High-resolution CT scans were performed at enrollment, and longitudinal data, including pulmonary function test (PFT) results, were collected every 12 months. Serum specimens were obtained at regular intervals and stored for future analysis. The baseline characteristics of the patients enrolled in this registry have been published previously, but the longitudinal analysis of this cohort was not completed due to a lapse in funding. Subsequently, the patient data and serum specimens were transferred to the National Disease Research Interchange and placed in the public domain. The passage of time while the data lay fallow offered a unique opportunity to understand the natural history of LAM in the pre-sirolimus era.
Materials and Methods
We retrieved de-identified data from the National Disease Research Interchange; which were linked to serum specimens collected during the NHLBI LAM registry patient visits. An imaging core consisting of expert thoracic radiologists calculated the radiologic disease severity based on the profusion of cystic changes seen on highresolution CT scans (e- Table 1 ). Serum VEGF-D measurements were performed on archival serum specimens in the Translational Trials Laboratory at Cincinnati Children's Hospital Medical Center, a College of American Pathologists/Clinical Laboratory Improvement Act-certified facility. Menopausal status of the participants was determined at the baseline visit based on history if clearly naturally or surgically menopausal, and in other cases by using measurements of serum follicle-stimulating hormone and estradiol levels.
To determine which of the patients in this cohort had either died or undergone lung transplantation in the interval between registry enrollment and our analysis, Social Security numbers for all registry participants were submitted to the National Death Index and the United Network for Organ Sharing databases. The National Death Index is a centralized database of death record information established by the Centers for Disease Control and Prevention and the National Center for Health Statistics to aid investigators in mortality ascertainment activities. The United Network for Organ Sharing, established by the US Congress in 1984, is a nonprofit organization that maintains a robust database containing information for every transplant that occurs in the United States.
PFTs were performed in a standard manner across all sites with strict monitoring and quality control. 8 The rate of decline of FEV 1 , and the association between FEV 1 slope and various clinical characteristics and serum biomarkers, was estimated by using a linear mixed effects model with random intercept and random slope. The model included time since the first measurement, age at the first measurement, the factor of interest, and the interaction between time and the factor of interest as fixed effects. The regression parameter for the interaction term was used to examine the association. Unstructured withinsubject correlation was assumed for the random error.
A Cox proportional hazards model for the incidence of lung transplantation or death was used to examine the association with clinical characteristics. Time to event was calculated as the number of years between the date of LAM diagnosis to the date of lung transplantation or date of death, whichever came first. Rightcensored time was based on the interval from the LAM diagnosis to the data censor date (December 31, 2014). For the multiple Cox regression model, we used stepwise selection by applying a significance level of 0.25 threshold for entering a variable into the model and a 0.15 threshold for retaining the variable in the model. The supremum test on martingale residuals was used for checking the proportional hazards assumption (no indication of violation was noted). All analyses were performed by using SAS version 9.4 (SAS Institute, Inc).
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Results

Baseline Characteristics
A total of 246 patients had enrolled in the NHLBI LAM registry. Sixteen patients were excluded because the diagnosis of LAM was incompletely substantiated or unconfirmed. Another 13 patients were excluded because they had undergone lung transplantation prior to enrollment in the registry. Data from the remaining 217 patients were analyzed (Tables 1, 2 ).
Analysis of PFTs
Among the 217 patients in the study cohort, 188 had at least two PFTs. Of these 188 patients, 161 patients had at least three PFTs, and 116 patients had at least four PFTs. Adequate serum specimens to allow VEGF-D measurement were available in 159 patients, and 165 patients had a baseline CT score computed. Longitudinal analysis of the PFTs revealed an average FEV 1 decline rate of 89 mL/year (Fig 1, Table 3 ).
Baseline disease severity was associated with the rate of FEV 1 decline, with faster rates of decline seen among patients with a higher initial FEV 1 (P < .0001), FVC (P ¼ .007), and CT score (P ¼ .02). Each one-unit increase in baseline FEV 1 % predicted, FVC % predicted, and CT score translated to acceleration in the rate of FEV 1 decline of 0.31 mL/year, 0.78 mL/year, and 3.53 mL/year, respectively. FEV 1 decline rates decreased with older age at diagnosis (P ¼ .05), with the rate of decline of FEV 1 reduced by 1.39 mL/year with every 1-year increase in the age at diagnosis. Menopausal status at enrollment had a major impact on the FEV 1 decline rates, with postmenopausal women declining 44 mL/year slower than the premenopausal women (74 mL/year vs 118 mL/ year; P ¼ .003). Patients with a positive bronchodilator response on spirometry tended to decline faster than patients without a bronchodilator response (113 mL/year vs 83 mL/year; P ¼ .09). Other baseline variables had no significant effect on the rate of decline of FEV 1 (Table 4 ).
Progression to Death or Transplantation
From the study cohort of 217 patients, 26 patients had died and 43 patients had undergone lung transplantation as of the data censor date of December 31, 2014. This outcome equates to 5-, 10-, 15-, and 20-year survival rates of 94%, 85%, 75%, and 64%, respectively, based on the composite endpoint of death or transplantation (Fig 2) .
Using a Cox proportional hazards model adjusted for age at diagnosis, we examined the characteristics that Table 2 ).
Finally, a multiple Cox regression model was used with stepwise variable selection to determine the combination of risk factors that were most predictive of outcome. The final model showed that menopausal status and baseline disease severity based on initial FEV 1 and DLCO are the major determinants of progression to death or transplantation (Figs 3-5, Table 5 ).
Discussion
The natural history of lung function decline in LAM has been defined primarily by retrospective cohort analyses and the placebo groups of randomized controlled clinical trials, yielding wide-ranging estimates of FEV 1 decline between 47 and 134 mL/year. 6, [9] [10] [11] [12] The divergent FEV 1 decline rates among these cohorts can largely be explained by ascertainment bias and varying baseline disease severity. Baseline PFT results have previously been reported to affect the future rate of decline, 9,11 with the slowest decline reported in patients with mild disease (FEV 1 > 70% predicted). 11 Although our data also indicate a relationship between baseline FEV 1 and the future rate of FEV 1 decline, the magnitude of effect is very small and opposite in direction (ie, higher baseline FEV 1 predicts faster rate of decline) to previous reports. Subsequently, we divided the study cohort into quartiles on the basis of initial FEV 1 and determined that the rate of FEV 1 decline was similar across all groups (Table 6 ). We therefore concluded that the association between baseline FEV 1 and future rate of decline is clinically insignificant, and we assert that rate of FEV 1 decline is See Table 2 legend for expansion of abbreviation. For the continuous variables, the parameter estimates reflect the effect on the rate of decline of FEV 1 per unit increase of the factor being studied. For example, the rate of decline of FEV 1 increases by 0.31 mL/year per 1% increase in the baseline FEV 1 % predicted.
chestjournal.org largely independent of baseline FEV 1 . This finding has important implications for treatment decisions in patients with mild but progressive disease and for the design of early intervention trials.
The rate of decline of FEV 1 was also higher in patients with greater profusion of parenchymal cysts on CT scanning. This finding suggests that CT assessment of disease burden can be helpful for prognostication, and it also highlights the need to develop automated and widely accessible methods to quantify radiologic disease burden as a useful prognostic biomarker.
Hormonal influences clearly play a role in the pathogenesis of LAM based on the near absolute restriction of symptomatic disease to female subjects, 1 expression of estrogen and progesterone receptors by LAM cells, 13 and reports of disease worsening with estrogen supplementation 14, 15 and pregnancy. 16, 17 Attenuation in the rate of FEV 1 decline after menopause as seen in our analysis further supports a role for estrogen in the pathogenesis of LAM. We found that patients with a positive bronchodilator response on spirometry exhibited a trend toward a faster rate of decline of FEV 1 and an increased risk of progression to death or transplantation (e -Fig 1) . A positive bronchodilator response was previously reported to be associated with more severe obstruction and a greater rate of FEV 1 decline in patients with LAM. 18 We found that patients with a positive bronchodilator response had a lower baseline FEV 1 (1.7 L, 57% predicted) compared with those without a bronchodilator response (2.2 L, 73% predicted) (P ¼ .0007) (e- Table 3 ). These data suggest that positive bronchodilator response may be a surrogate for more advanced airway involvement with LAM 19 and may be a potential prognostic biomarker.
Several traditional prognostic biomarkers of disease progression in LAM did not correlate with the rate of decline of FEV 1 in the present study. For example, baseline serum VEGF-D was not significantly associated with the rate of FEV 1 decline. Several groups have validated the value of VEGF-D as a prognostic biomarker, 20 while others have failed to show an association between baseline VEGF-D levels and future decline. 21, 22 Although the reasons for these divergent results are not known, several explanations are possible for the lack of a correlation in our study, including the following: (1) the accuracy of serum VEGF-D measurement may have been affected by storage at -80 C for > 15 years; (2) the VEGF-D relation with rate of lung function decline may only apply to patients with more severe disease; or (3) the extent of lymphatic involvement in the two cohorts may have been different. With respect to the last point, in an analysis of 111 patients with LAM at the National Institutes of Health (NIH), elevated levels of serum VEGF-D were shown to correlate with the presence of lymphangioleiomyomas and/or lymphadenopathy, 22 and studies from the NIH 23 and Japan 24 have shown that response to therapy is better in patients with lymphatic involvement. It is possible that the correlation between serum VEGF-D and the rate of decline of FEV 1 is limited to the subset of LAM patients with a lymphatic phenotype. Unfortunately, the presence of lymphangioleiomyomas and/or lymphadenopathy was not recorded during the registry visits, and we were unable to conduct a subgroup analysis to investigate this hypothesis.
Some reports suggest that patients with TSC-LAM have milder and less progressive disease compared with those with sporadic LAM. 25, 26 More recently, the NIH Intramural group has reported that the rate of lung function decline is similar when TSC-LAM and patients with sporadic LAM are matched for baseline disease severity. 27 Ascertainment bias may certainly play a role in these differing results because screening can identify TSC-LAM in earlier stages than sporadic LAM is typically discovered. In our study cohort, there was no difference between patients with TSC-LAM and sporadic LAM in the rate of decline of FEV 1 , in keeping with the conclusions of the NIH Intramural study, 27 or in the future risk of progression to death/ transplantation.
Pneumothorax can be a sentinel event that leads to early diagnosis of LAM and has been reported to identify a cohort with a more favorable prognosis, 28, 29 likely reflecting a lead-time bias. In the present cohort, 55% of the patients (120 of 217) had at least one spontaneous pneumothorax. The mean age at LAM diagnosis was 37.6 years for women in the pneumothorax subgroup compared with 44.5 years in the non-pneumothorax subgroup (P < .0001), consistent with a role for pneumothorax in bringing the diagnosis to light earlier.
However, neither the occurrence of spontaneous pneumothorax nor the number of spontaneous See Table 2 legend for expansion of abbreviation. The results from our analysis support these more recent findings, with 5-, 10-, 15-, and 20-year survival rates of 94%, 85%, 75%, and 64%.
Relatively little is known about the variables that predict mortality in LAM; lower FEV 1 /FVC ratios, 31 worse histologic findings, 33 presentation with dyspnea, 28 and the need for supplemental oxygen 29 are the major reported factors that are associated with an increased risk of death. Our data further illustrate that lower lung function is associated with decreased survival. In addition, our study shows for the first time that postmenopausal women with LAM have a better survival rate than premenopausal women. The improved survival, coupled with a reduced rate of FEV 1 decline among postmenopausal women, suggests that menopause is a milestone that segregates patients with LAM into two different subgroups with markedly different outcomes.
Strengths
This analysis was the largest prospective natural history study of women with LAM, and the only one to include rigorously validated PFT, survival, and transplantation endpoints. In addition, these data represent perhaps the last opportunity to understand disease progression in the pre-sirolimus era and will be a useful comparator for future studies to determine the impact of mTOR therapy on survival. All PFTs were conducted in a limited number of predefined, American Thoracic Society/ European Respiratory Society-compliant laboratories, using postbronchodilator measurements and strict quality control. The serum VEGF-D assays were performed in a College of American Pathologists/ Clinical Laboratory Improvement Act-certified laboratory. This dataset can aid in the development of a LAM-specific disease severity score that will be useful for prognostication and treatment decisions. In addition, this publicly available, prospective natural history dataset and linked serum and plasma specimens can be used by the LAM research community as a resource for the discovery and development of novel LAM-specific biomarkers.
Limitations
Our study has several limitations. The MILES trial showing the efficacy of sirolimus in LAM was published in 2011. 6 The impact of sirolimus on progression to death/lung transplantation has not been studied. Because our data censor date (December 2014) overlapped with the early use of sirolimus in LAM, it is possible that some of the estimates affecting progression to death/lung transplantation were skewed by treatment with sirolimus. To address this concern, we performed a sensitivity analysis with a data censor date of December 31, 2010 (prior to publication of MILES). Excluding death/transplantation beyond 2010 resulted in the exclusion of 15 events of a total of 69 events, and had no impact on the overall survival or the prognostic variables.
The majority of patients enrolled in the NHLBI LAM registry were enrolled at the NIH, a group that has published extensively on the natural history of LAM. 9, 18, 27, 33 Although there is clearly some overlap in the present cohort and populations reported in previous NIH studies, the longitudinal analysis of the LAM registry data has never been reported, and these previous analyses did not include the biochemical assessment of menopausal status, analysis of VEGF-D as a long-term prognostic biomarker, or prospective assessment of survival and transplantation outcomes.
Finally, menopausal status was obtained only at baseline, and transitions to menopause during the study were not recorded. In addition, although better outcomes in postmenopausal women seem biologically plausible, given the known hormonal influences on the pathogenesis of LAM, the potential influence of survival bias on this finding cannot be completely excluded.
Conclusions
The present study highlights that LAM is chronic, progressive disease with a rate of lung function decline that is roughly three times higher than that of healthy subjects. Postmenopausal women decline at a significantly lower rate than premenopausal women. The median transplant-free survival in untreated women with LAM is > 20 years and is significantly affected by the baseline PFT results and menopausal status.
